Welcome to our dedicated page for Verona Pharma news (Ticker: VRNA), a resource for investors and traders seeking the latest updates and insights on Verona Pharma stock.
Verona Pharma plc was a respiratory biopharmaceutical company whose updates centered on Ohtuvayre (ensifentrine), a selective dual PDE3 and PDE4 inhibitor for maintenance treatment of chronic obstructive pulmonary disease in adults. Company news covered Ohtuvayre commercialization, analyses from the Phase 3 ENHANCE studies in COPD, respiratory-disease pipeline work including non-cystic fibrosis bronchiectasis, and financial results tied to the product launch.
Verona Pharma became a wholly owned subsidiary of Merck after the completed acquisition in 2025, and its American Depositary Shares ceased trading on the Nasdaq Global Market. Later corporate news reflects the completed status change, material agreements, shareholder voting matters, capital-structure disclosures, and governance matters.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.